AbbVie Inc.

The Company does not obtain collateral for its accounts receivable.The percentages of revenue recognized from significant collaborative partners of the Company in the years ended December 31, 2025 and 2024 and the account receivable balances, net of any payables due, as of December 31, 2025 and 2024 are included in the following table: AccountsReceivable Revenue December 31, Year Ended December 31, 2025 2024 2025 2024 Collaborative Partner: AbbVie (North America and Europe) 99% 99% 100% 99% Property and EquipmentProperty and equipment, including leasehold improvements, are recorded at cost, and are depreciated when placed into service using the straight-line method based on their estimated useful lives as follows: Estimated Useful LifeAsset Description (In Years)Laboratory equipment 5Computer and office equipment 3Furniture and fixtures 7Software 3 Included in property and equipment are certain costs of software obtained for internal use.

The percentages of revenue recognized from significant collaborative partners of the Company in the years ended December 31, 2024, 2023, and 2022 and the account receivable balances, net of any payables due, at December 31, 2024 and 2023 are included in the following table: AccountsReceivable Revenue December 31, Year Ended December 31, 2024 2023 2024 2023 2022 Collaborative Partner: AbbVie (North America and Europe) 99% 87% 99% 98% 98% Property and Equipment Property and equipment, including leasehold improvements, are recorded at cost, and are depreciated when placed into service using the straight-line method based on their estimated useful lives as follows: Estimated Useful LifeAsset Description (In Years)Laboratory equipment 5Computer and office equipment 3Furniture and fixtures 7Software 3 Included in property and equipment are certain costs of software obtained for internal use.

The percentages of revenue recognized from significant collaborative partners of the Company in the years ended December 31, 2023, 2022 and 2021 and the account receivable balances, net of any payables due, at December 31, 2023 and 2022 are included in the following table: AccountsReceivable Revenue December 31, Year Ended December 31, 2023 2022 2023 2022 2021 Collaborative Partner: AbbVie (North America and Europe) 87% 80% 98% 98% 98%

Following the acquisition of Allergan by AbbVie, the Company determined that AbbVie is not a related party to the Company (Note 15).The percentages of revenue recognized from significant collaborative partners of the Company in the years ended December 31, 2022, 2021 and 2020 as well as the account receivable balances, net of any payables due, at December 31, 2022 and 2021 are included in the following table: AccountsReceivable Revenue December 31, Year Ended December 31, 2022 2021 2022 2021 2020 Collaborative Partner: AbbVie (North America and Europe) 80% 81% 98% 98% 96% Property and Equipment Property and equipment, including leasehold improvements, are recorded at cost, and are depreciated when placed into service using the straight-line method based on their estimated useful lives as follows: Estimated Useful Life Asset Description (In Years) Laboratory equipment 5 Computer and office equipment 3 Furniture and fixtures 7 Software 3 Included in property and equipment are certain costs of software obtained for internal use.

Following the acquisition of Allergan by AbbVie, the Company determined that AbbVie is not a related party to the Company (Note 16).The percentages of revenue recognized from significant collaborative partners of the Company in the years ended December 31, 2021, 2020 and 2019 as well as the account receivable balances, net of any payables due, at December 31, 2021 and 2020 are included in the following table: AccountsReceivable Revenue December 31, Year Ended December 31, 2021 2020 2021 2020 2019 Collaborative Partner: AbbVie (North America and Europe) 81% 76% 98% 96% 78% Astellas (Japan) 1% 1% 1% 1% 13% Property and Equipment Property and equipment, including leasehold improvements, are recorded at cost, and are depreciated when placed into service using the straight-line method based on their estimated useful lives as follows: Estimated Useful Life Asset Description (In Years) Laboratory equipment 5 Computer and office equipment 3 Furniture and fixtures 7 Software 3 Included in property and equipment are certain costs of software obtained for internal use.

Following the acquisition of Allergan by AbbVie, the Company determined that AbbVie is not a related party to the Company (Note 17).The percentages of revenue recognized from significant collaborative partners of the Company in the years ended December 31, 2020, 2019 and 2018 as well as the account receivable balances, net of any payables due, at December 31, 2020 and 2019 are included in the following table: AccountsReceivable Revenue December 31, Year Ended December 31, 2020 2019 2020 2019 2018 Collaborative Partner: AbbVie (North America and Europe) 76% 90% 96% 78% 77% Astellas (Japan) 1% 8% 1% 13% 20% For the years ended December 31, 2020, 2019 and 2018, no additional customers accounted for more than 10% of the Company’s revenue.

AbbVie — 4 % 17 %

AbbVie accounted for approximately 11% and 12% of our net revenues for the three and six months ended June 30, 2015, respectively.

AbbVie accounted for approximately 12% of our net revenues for the three months ended March 31, 2015.